KULLING ABI: Open Payments
NPI 1104237684 · KENT, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,003 in 104 payments from 11 companies in 2025. Trend: 2023 $1,087 · 2024 $1,554 · 2025 $2,003
Food & beverage: $2,003
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $509 |
| Otsuka America Pharmaceutical, Inc. | 21 | $415 |
| Lundbeck LLC | 15 | $269 |
| Alkermes, Inc. | 10 | $223 |
| Vanda Pharmaceuticals Inc. | 13 | $191 |
| Indivior Inc. | 6 | $117 |
| ABBVIE INC. | 4 | $87 |
| Janssen Pharmaceuticals, Inc | 4 | $65 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $47 |
Products named: CAPLYTA, REXULTI, ARISTADA, FANAPT, ABILIFY MAINTENA, SUBLOCADE, VRAYLAR, INVEGA SUSTENNA.
Industry payments across OH — which companies pay providers there.
